MINRIN® Orally Disintegrating Tablet (Fast Dissolving Desmopressin) and Tablets in Treatment of Primary Nocturnal Enuresis (MELT)

Ferring

Status: Completed

Conditions: Nocturnal Enuresis

Study type: Observational

Funder types: Industry

Identifiers

NCT01368913

000018

Details and patient eligibility

About

Desmopressin in treatment of nocturnal enuresis (bedwetting).

Enrollment: 138 patients

Sex: All

Ages: 5+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Treatment of primary nocturnal enuresis within an overall therapeutical concept, eg, in cases of failure of other non-medicinal therapies or with indication of a medicinal therapy caused by nocturnal ADH deficiency
• The patients and their parents have been informed about the study and have given their written consent for participation.

Exclusion criteria

• The prescription of Minirin® tablets / Minirin® orally disintegrating tablet (fast dissolving desmopressin) is contraindicated

Trial design

138 participants in 2 patient groups

Patients treated with orally disintegrating tablet

Patients treated with tablets